Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria~* Males and females between 18 and 85 years of age at screening.~* Body weight is ≥45 kg at screening.~* Diagnosed with HCM per the following criteria:~  * Has left ventricular (LV) hypertrophy with non-dilated LV chamber in the absence of other cardiac disease.~ * Has minimal wall thickness ≥15 mm (minimal wall thickness ≥13 mm is acceptable with a positive family history of HCM or with a known disease-causing gene mutation).~* Adequate acoustic windows for echocardiography.~* For Cohorts 1, 2 and 3 has LVOT-G during screening as follows:~  * Resting gradient ≥50 mmHg OR~ * Resting gradient ≥30 mmHg and \<50 mmHg with post-Valsalva LVOT-G ≥50 mmHg~* For Cohort 4 has resting and post-Valsalva LVOT-G \< 30 mmHg at the time of screening~* For Cohort 4 has elevated NT-proBNP \> 300 pg/mL at the time of screening~* LVEF ≥60% at screening.~* New York Heart Association (NYHA) Class II or III at screening.~* Patients on beta-blockers, verapamil, diltiazem, or ranolazine should have been on stable doses for \>4 weeks prior to randomization and anticipate remaining on the same medication regimen during the study.~* For Cohort 3: Patients must be taking disopyramide. Patients should have been on stable disopyramide doses for \>4 weeks prior to screening and anticipate remaining on the same medication regimen during the study.~Exclusion Criteria~* Aortic stenosis or fixed subaortic obstruction.~* Known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM (eg, Noonan syndrome, Fabry disease, amyloidosis).~* History of LV systolic dysfunction (LVEF \<45%) at any time during their clinical course.~* Documented history of current obstructive coronary artery disease (\>70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.~* Has been treated with septal reduction therapy (surgical myectomy or percutaneous alcohol septal ablation) or has plans for either treatment during the study period (Cohorts 1, 2, and 3 only). Patients having undergone septal reduction therapy \> 12 months prior to screening who remain symptomatic from nHCM, and who meet all other criteria for inclusion, may be enrolled in Cohort 4.~* For Cohorts 1, 2 and 4: Has been treated with disopyramide or antiarrhythmic drugs that have negative inotropic activity within 4 weeks prior to screening. (For Cohort 3, use of disopyramide is required).~* Has any ECG abnormality considered by the investigator to pose a risk to patient safety (eg, second degree atrioventricular block type II).~* Paroxysmal atrial fibrillation or flutter documented during the screening period.~* Paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) ≤6 months prior to screening. (This exclusion does not apply if atrial fibrillation has been treated with anticoagulation and adequately rate-controlled for \>6 months).~* History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to screening.~* Has received prior treatment with CK-3773274 or mavacamten.~* For Cohort 4: has any documented history of LVOT-G ≥ 30 mmHg at rest, with Valsalva, or with exercise (for subjects who have had prior septal reduction therapy, this exclusion criteria only applies to gradients detected following septal reduction therapy).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CK-3773274 - Cohort 1 (Obstructive HCM) (Type: EXPERIMENTAL): Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
- Placebo - Cohort 1 (Obstructive HCM) (Type: PLACEBO_COMPARATOR): Subjects will receive placebo for up to 10 weeks
- CK-3773274 - Cohort 2 (Obstructive HCM) (Type: EXPERIMENTAL): Subjects will receive doses 10 - 30 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks
- Placebo - Cohort 2 (Obstructive HCM) (Type: PLACEBO_COMPARATOR): Subjects will receive placebo for up to 10 weeks
- CK-3773274 & disopyramide - Cohort 3 (Obstructive HCM) (Type: EXPERIMENTAL): Subjects will receive doses 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks while taking disopyramide
- CK-3773274 - Cohort 4 (non-obstructive HCM) (Type: EXPERIMENTAL): Subjects will receive doses of 5 - 15 mg of CK-3773274 with dose levels guided by echocardiography assessments for up to 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).